About NexCGT-2027
Next-Generation Cell & Gene Therapy Conference (NexCGT-2027) will be held from June 2-4, 2027, in Boston, MA, and is proudly organized by Impact Research Communications.
As the inaugural edition of the conference, NexCGT-2027 aims to establish a premier international platform for scientists, clinicians, biotechnology innovators, pharmaceutical leaders, regulatory experts, and industry professionals working in the rapidly evolving field of Cell & Gene Therapy. The conference will bring together global experts to discuss the latest scientific discoveries, technological advancements, translational research, and commercialization strategies shaping the future of advanced therapeutics.
Why Attend NexCGT-2027
NexCGT-2027 brings together academia, biotechnology companies, pharmaceutical industries, investors, and healthcare organizations to foster impactful collaborations and accelerate innovation in Cell & Gene Therapy.
Explore the latest advances in gene editing, CRISPR technologies, engineered cell therapies, regenerative medicine, RNA therapeutics, and translational research through keynote presentations, expert panels, and interactive scientific sessions.
Connect with leading researchers, clinicians, biotech innovators, regulatory experts, investors, and industry leaders through networking sessions, partnering opportunities, and business interactions.
Gain insights into manufacturing, regulatory pathways, AI-driven innovations, commercialization strategies, and emerging technologies shaping the future of advanced therapies and precision medicine.
Scientific Sessions
- Current State and Future Directions in Cell & Gene Therapy
- Translational Research Strategies for Accelerating Clinical Development
- Advances in Gene Editing Technologies and Therapeutic Applications
- Stem Cell and Regenerative Medicine: Clinical Translation and Emerging Therapies
- Cell Reprogramming and Next-Generation Regenerative Approaches
- RNA-Based Therapeutics and Gene Modulation Technologies
- Non-Viral and Novel Gene Delivery Platforms
- Personalized and Precision Cell & Gene Therapies
- Translational Challenges in Rare and Genetic Diseases
- Clinical Development of Cell & Gene Therapies for Oncology
- Neurodegenerative and Neuromuscular Disease Therapeutics
- Emerging Therapeutic Applications Beyond Rare Diseases
- Real-World Evidence and Long-Term Patient Outcomes
- Clinical Trial Design and Patient-Centric Development Strategies
- CRISPR, Base Editing, Prime Editing and Beyond
- Precision Genome Engineering for Next-Generation Therapies
- In Vivo vs Ex Vivo Gene Editing Strategies
- Engineering Immune Cells: CAR-T, CAR-NK, TCR-T and Beyond
- Multiplex Gene Editing and Synthetic Biology Approaches
- Gene Editing for Hematological and Inherited Disorders
- Engineering Stem Cells for Regenerative Applications
- Novel Vector Technologies and Targeted Delivery Systems
- AI-Driven Target Identification and Therapeutic Design
- Gene Editing Safety, Off-Target Analysis and Risk Mitigation
- Translational Models for Gene Editing and Cell Therapy Development
- Emerging Genome Engineering Platforms and Future Technologies
- Clinical Trial Design for Cell & Gene Therapies
- Patient Recruitment, Diversity and Retention Strategies
- Biomarkers, Companion Diagnostics and Patient Selection
- Clinical Safety Monitoring and Long-Term Follow-Up
- Real-World Evidence and Post-Marketing Data Generation
- Translational Medicine Approaches for Accelerating Development
- Clinical Success Stories and Lessons Learned
- Global Clinical Development Strategies
- Digital Health and AI in Clinical Trial Management
- Patient Access and Treatment Adoption
- Scaling Cell & Gene Therapy Manufacturing for Commercial Success
- Process Development and Tech Transfer Strategies
- Viral Vector Manufacturing and Capacity Expansion
- Next-Generation Non-Viral Manufacturing Platforms
- Automation, Robotics and Digital Manufacturing
- AI and Data Analytics in Bioprocess Optimization
- GMP Compliance and Quality-by-Design Approaches
- Quality Control, Release Testing and Comparability
- Closed-System Manufacturing Technologies
- Decentralized and Point-of-Care Manufacturing Models
- Cold Chain Logistics and Global Distribution Strategies
- Supply Chain Resilience and Risk Management
- CDMO Partnerships and Outsourcing Models
- Cost Reduction and Manufacturing Economics
- Sustainable Manufacturing for Advanced Therapies
- Global Regulatory Landscape for Cell & Gene Therapies
- FDA, EMA and International Regulatory Perspectives
- Accelerated Approval Pathways and Expedited Programs
- Regulatory Considerations for Gene Editing Technologies
- CMC Strategies for Regulatory Success
- Pharmacovigilance and Long-Term Safety Monitoring
- Market Access and Reimbursement Strategies
- Value Demonstration and Health Economics
- Innovative Pricing Models for Advanced Therapies
- Commercial Launch Readiness and Market Entry Planning
- Intellectual Property, Licensing and Technology Transfer
- Strategic Partnerships, M&A and Investment Trends
- Venture Capital and Funding Opportunities in Cell & Gene Therapy
- Commercial Success Stories and Lessons from Approved Products
- Academia-Industry Collaboration Models
- Building Successful Translational Research Ecosystems
- Biotech Startups and Emerging Innovation Platforms
- Investment Trends in Cell & Gene Therapy
- Strategic Alliances and Partnering Opportunities
- Technology Commercialization and Licensing Strategies
- Public-Private Partnerships in Advanced Therapeutics
- Future Outlook: The Next Decade of Cell & Gene Therapy